Back to Journals » Therapeutics and Clinical Risk Management » Volume 14
Review
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
23,688 | Dovepress* | 13,548+ | 2,185 | 15,733 | |
PubMed Central* | 10,140 | 1,728 | 11,868 | ||
Totals | 23,688 | 3,913 | 27,601 | ||
*Since 31 May 2018 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
5 | 0 | 0 | 0 | 1 | 4 |
View citations on PubMed Central and Google Scholar